home / stock / bbi / bbi news

BBI News and Press, Brickell Biotech Inc. From 07/29/21

Stock Information
Company Name: Brickell Biotech Inc.
Stock Symbol: BBI
Market: NYSE
Menu
BBI BBI Quote BBI Short BBI News BBI Articles BBI Message Board
Get BBI Alerts

News, Short Squeeze, Breakout and More Instantly...
BBI - Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021

BOULDER, Colo., July 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced...
BBI - Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter's Option to Purchase Additional Shares

BOULDER, Colo., July 22, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debili...

BBI - Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million

BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilita...

BBI - Brickell Biotech announces $5M capital raise

Brickell Biotech (BBI) enters underwriting agreement with H.C. Wainwright under which the underwriter has agreed to purchase on a firm commitment basis ~8M shares at a price to the public of $0.62 per share.Closing is expected to occur on or about July 22, 2021.Underwriter's 30-day optio...
BBI - Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock

BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debili...

BBI - Brickell Biotech to Participate at William Blair's Biotech Focus Conference 2021

BOULDER, Colo., July 06, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today ann...

BBI - Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidro

BOULDER, Colo., June 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debili...
BBI - Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan

BOULDER, Colo., June 24, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debili...

BBI - Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

BOULDER, Colo., June 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today ann...

BBI - Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2021 Results - Earnings Call Transcript

Brickell Biotech, Inc. (BBI) Q1 2021 Earnings Conference Call May 13, 2021 16:30 ET Company Participants Garth Russell - Investor Relations, LifeSci Advisors Robert Brown - Chief Executive Officer Deepak Chadha - Chief R&D Officer Bert Marchio - Chief Financial Officer Conference Call Par...
Previous 10 Next 10